Biomarin Pharmaceutical Inc. · NASDAQ:BMRN
Biomarin Pharmaceutical — Q3 2026 Earnings Presentation
24 slides from Biomarin Pharmaceutical's earnings presentation, Nov 2, 2026
Slide 1: Third Quarter 2026 Financial Results
Third Quarter 2026 Financial Results November 2, 2026 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expecta
Slide 3: Q3'26 Financial Results Agenda
Q3’26 Financial Results Agenda: 1 Key Business Updates 2 Commercial Update 3 Research & Development Update 4 Financial Results 5 Q&A Alexander Hardy Cristin Hubbard Greg Friberg Brian Mueller Chief Executive Officer Chief Commercial Officer Chief R&D Officer Chief Financial Officer
Slide 4: Q3'26 Key Business Updates
Q3’26 Key Business Updates Alexander Hardy Chief Executive Officer 4
Slide 5: Q3: Execution Across the Business while Investing in the Future
Q3: Execution Across the Business while Investing in the Future STRONG Q3’26 PERFORMANCE AMICUS VALUE CREATION BUILDING PIPELINE MOMENTUM 4 New Pipeline Assets in $1.025B ▲ 32%Y/Y +13% +69% 2026; Data and Approvals Total Revenue Growth; GALAFOLD POMBILITI + OPFOLDA First $1B+ Revenue Quarter Q3’26 P
Slide 6: Commercial Update
Commercial Update Cristin Hubbard Chief Commercial Officer 6
Slide 7: Strong GALAFOLD and POMBILITI + OPFOLDA Patient Growth in Q3
Metabolic GROWTH Conditions Strong GALAFOLD and POMBILITI + OPFOLDA Patient Growth in Q3 • +13% Y/Y patient growth • +69% Y/Y patient growth • $152M Q3 revenue • $49M Q3 revenue • Expanded diagnosis and treatment, • Patient switching supported by a with deeper penetration across differentiated clini
Slide 8: Metabolic Conditions: Diversified Portfolio Drove Record Results
Metabolic GROWTH Conditions Metabolic Conditions: Diversified Portfolio Drove Record Results Metabolic Conditions Q3’26 Revenue Q3’26 Dynamics In millions, except percentages $744M, +44% Y/Y1 • +44% Y/Y revenue growth, driven largely by the first full quarter of GALAFOLD and POMBILITI + OPFOLDA +18%
Slide 9: Skeletal Conditions: Global Growth and Continued Leadership
Skeletal Conditions Skeletal Conditions: Global Growth and Continued Leadership Revenue Q3’26 Dynamics In millions, except percentages • +12% Y/Y revenue growth; ~17% increase in the number of children treated globally Y/Y • > 75% of revenue generated outside of the U.S. +12% • Large international o
Slide 10: Research & Development Update
Research & Development Update Greg Friberg Chief R&D Officer 10
Slide 11: Pipeline Momentum: Four New Assets in 2026, Multiple Catalysts Ahead
Pipeline Momentum: Four New Assets in 2026, Multiple Catalysts Ahead Program Preclinical Phase 1 Phase 2 Phase 3 Key Highlights VOXZOGO • sNDA filing accepted Hypochondroplasia • PDUFA action date: May 30, 2027 VOXZOGO • Phase 2 data expected in 2027 Idiopathic Short Stature BMN 333 • Phase 2/3 regi
Slide 12: BMN 450: Potential First Subcutaneous ERT for Fabry Disease
BMN 450: Potential First Subcutaneous ERT for Fabry Disease Long-acting enzyme replacement therapy designed for subcutaneous dosing Target Product Profile BMN 450 • Human recombinant α-Gal A designed to extend half-life and improve stability relative to currently available ERTs • Subcutaneous dosing
Slide 13: BMN 440 for Hypophosphatasia: Differentiated Mechanism of Action
BMN 440 for Hypophosphatasia: Differentiated Mechanism of Action Directly inhibits ENPP1 upstream of PPi, offering a substrate reduction approach for HPP Deficient alkaline phosphatase activity causes PPi accumulation, impairing bone mineralization and Target Product Profile contributing to musculos
Slide 14: POMBILITI + OPFOLDA Demonstrates Durable Outcomes Through Five Years in LOPD
POMBILITI + OPFOLDA Demonstrates Durable Outcomes Through Five Years in LOPD Long-term durability across motor function, pulmonary function, biomarker response, and safety Key Highlights Biomarker improvement: Sustained serum CK reductions in both ERT-experienced and ERT- naïve patients. Long-term p
Slide 15: Q3'26 Financial Results
Q3’26 Financial Results Brian Mueller Chief Financial Officer 15
Slide 16: Q3 Financial Highlights
Q3 Financial Highlights Q3 2026 Results Total Revenues • $1,025M, +32% Y/Y, primarily driven by addition of Y/Y GALAFOLD and POMBILITI + OPFOLDA In millions, except percentages and per Q3’26 share amounts Change • Royalty and Other Revenues now include royalties from Ascendis Total Revenues $1,025 +
Slide 17: Updated Full-year 2026 Guidance
Updated Full-year 2026 Guidance Prior Guidance Updated Guidance Midpoint Growth (In millions, except per share amounts) As of August 6, 2026 As of November 2, 2026 (Y/Y) Total Revenues $3,875 to $3,925 $3,800 to $3,900 20% Metabolic Conditions $2,725 to $2,775 $2,675 to $2,750 29% VOXZOGO $1,000
Slide 18: iIOMARIN
iIOMARIN B <x 08 S) ee ee
Slide 19: Appendix
Appendix Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information
Slide 20: Reconciliation of GAAP Reported Net Income (Loss) to Non-GAAP Income
Reconciliation of GAAP Reported Net Income (Loss) to Non-GAAP Income(1) (In millions) Please refer to slide 24 for footnotes to the table 20
Slide 21: Reconciliation of GAAP and Non-GAAP COS, R&D, and SG&A Expenses
Reconciliation of GAAP and Non-GAAP COS, R&D, and SG&A Expenses(1) (In millions) Please refer to slide 24 for footnotes to the table 21
Slide 22: Reconciliation of GAAP Income (Loss) from Operations to Non-GAAP Income from Operations
Reconciliation of GAAP Income (Loss) from Operations to Non-GAAP Income from Operations(1) (In millions, except percentages) Please refer to slide 24 for footnotes to the table 22
Slide 23: Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS
Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS(1) (In U.S. dollars) Please refer to slide 24 for footnotes to the table 23
Slide 24: Reconciliation of GAAP Weighted-Average Diluted Shares to Non-GAAP
Reconciliation of GAAP Weighted-Average Diluted Shares Outstanding to Non-GAAP Weighted-Average Diluted Shares Outstanding(1) (In millions) (1) Certain amounts may not sum or recalculate due to rounding. (2) Stock-based compensation expense recorded in SG&A for the nine months ended September 30, 20
BioMarin Pharmaceutical — Q3 2026 Earnings Presentation on 6ix